# A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

> **NCT03605706** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 396 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** FOLFOX4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03605706
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-31
- **Primary completion:** 2023-02
- **Final completion:** 2023-12
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605706, "A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03605706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*